BREAKING: Revolutionary cancer drug research reported in The Economist funded by Drug Patent Owner
Cross posted from: https://europe.pub/post/13201474
Check out the amazing Conclusion from the primary source: "Daraxonrasib was associated with treatment-related adverse events of grade 3 or higher in one third of patients with previously treated RAS-mutated PDAC; antitumor activity was also reported." 😑
Fucken market manipulators, smdh. Just let Black-Scholes-Merton function naturally.
https://www.economist.com/science-and-technology/2026/06/12/treating-pancreatic-tumours-may-have-revealed-cancers-master-switchOpen linkView original on lemmy.world